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Regarding “A prospective study of ultrasound-guided
thrombin injection of femoral pseudoaneurysm: A
trend toward minimal medication”
It is with interest I read the article by Olsen et al.1 Their data
support the findings that lower doses of thrombin are effective for
treatment of femoral pseudoaneurysm, as previously reported by
Reeder et al.2
However, there appear to be troublesome omissions with
regard to their methods. In this prospective study there is no
mention of adherence to the principles of the Declaration of
Helsinki.3 Point 13 of the Declaration states that “The design and
performance of each experimental procedure involving human
subjects should be clearly formulated in an experimental protocol.
This protocol should be submitted for consideration, comment,
guidance, and where appropriate, approval to a specially appointed
ethical review committee, which must be independent of the
investigator, the sponsor or any other kind of undue influence.”
The Journal of Vascular Surgery publication rules stipulate that
“Manuscripts that involve research conducted on human subjects
must follow the principles outlined in the Declaration of Helsinki
and include a statement in the Methods section that the experi-
mental protocol and informed consent were approved by the
institutional review board and that all subjects gave informed
consent.” In the article by Olsen and colleagues, no mention is
made of informed patient consent or of institutional review board
approval, again, required of all studies involving human research.4
Adherence to these rules is mandatory to ensure the highest ethical
standards when conducting biomedical research.
In addition, while exclusion criteria were given, no mention
was made regarding the number of patients excluded from the
study. Did any eligible patients refuse participation in the study?
Were any eligible patients not included in the study for any other
reason?
Prospective study designs require that informed consent be
obtained, institutional review board approval be obtained, and
study end points be defined before patient enrollment in a study.
Olsen and colleagues do not provide enough information in their
article to determine whether these rules were followed. One could
suppose that the patients treated in their study would have been
treated similarly in the absence of a defined protocol, and thus
informed consent for participation in a trial was unnecessary be-
cause their treatment conformed to standard of care. If so, this
study should then be more appropriately called a retrospective
analysis, not a prospective study.
Ashutosh V. Rao, MD
Harvard University School of Medicine
Brigham & Women’s Hospital
Boston, Mass
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Reply
We appreciate your comments, and we hope this will clarify
your concerns. This was not an “experimental procedure involving
human subjects.” This method of treatment of common femoral
pseudoaneurysm is our standard practice, as it is in many other
centers. In our practice, ultrasound-guided thrombin injection is
attempted, and if it is unsuccessful, a second attempt is made. If the
second attempt fails, surgical repair is implemented. Please note
that treatment options including compression, open surgical re-
pair, and thrombin injection were discussed with each patient. In
addition, risks and benefits of each intervention were discussed.
You are correct in stating that the institutional review board
must approve the off-label use of a drug if its use involves human
subjects and you are researching its effect. The board is not
required to review off-label use of a drug if “it is intended to be
solely the practice of medicine,” which it was in our case. This is
our standard practice for treating pseudoaneurysm. As the data
were reviewed, it was evident that less thrombin was necessary to
successfully thrombose a pseudoaneurysm. Perhaps a better pro-
spective study would be to establish a dilution and administer a
single amount, and determine if that would cause thrombosis,
rather than report a trend.
During the study period, 2 patients were considered “outli-
ers.” One patient with a pseudoaneurysm less than 2.0 cm chose
compression therapy. This was successful, but required two inter-
vals of compression. The other patient, with a pseudoaneurysm
greater than 8 cm, underwent successful ultrasound-guided
thrombin injection. This patient would have undergone open
surgical repair if only the size of the pseudoaneurysm was consid-
ered. However, the cardiologist believed she was at high-risk for
anesthesia and surgery. Neither of these patients was included in
the study.
If a prospective study requires that we must establish different
dosing schedules before initiation of the study, rather than pro-
spectively gather data, documenting the dosage used in each case,
then we lack this variable. The data were gathered prospectively
and reviewed retrospectively. We have a database established for
our various procedures. If one of us chose to follow the outcomes
of a procedure, there is the option to retrospectively review previ-
ous cases or begin following up all patients treated during a certain
period. If a prospective study requires that last factor, then you are
correct in deeming this a retrospective study.
Thank you for you comments.
Dawn M. Olsen, PA-C, MMSc
Julio A. Rodriguez, MD
Arizona Heart Institute
Phoenix, Ariz
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